Is Botulax as Good as Xeomin | Purity, Proteins, and Resistance
Xeomin removes all complex proteins through its patented purification process, achieving an antibody production rate close to 0%.
Compared to Botulax, which contains complex proteins and carries a potential risk of drug resistance, Xeomin’s ultra-high purity significantly reduces the probability of immune tolerance caused by long-term injections, making it the professional choice for ensuring continuous and stable clinical efficacy.
Purity
Xeomin removes all complex proteins through patented technology. Its active ingredient is a pure 150kDa neurotoxin, with a total protein load of approximately 0.44ng per 100 units.
Botulax retains accessory proteins, including hemagglutinin, with a molecular weight of 900kDa and a protein load of approximately 5ng/100U.
Purity indicators determine how frequently the immune system detects foreign proteins.
Xeomin’s extremely low protein content reduces the possibility of producing neutralizing antibodies to an extremely low level, ensuring stability across multiple uses.
Structural Components
The biological base structure of Botulinum Toxin Type A is a neurotoxin with a molecular weight of 150kDa, composed of a 100kDa heavy chain and a 50kDa light chain connected by a disulfide bond.
In its natural synthetic state, this 150kDa active molecule is usually wrapped in a series of non-toxic proteins, forming a massive complex.
Botulax belongs to this traditional complex structure, and its finished product contains the complete 900kDa complex.
In addition to the 150kDa neurotoxin, the components of this 900kDa complex include approximately 750kDa of complex proteins (NAPs), mainly composed of hemagglutinin (HA) and non-toxic non-hemagglutinin (NTNH) proteins.
In contrast, Xeomin uses the patented XTRACT purification technology to completely strip away this 750kDa complex protein shell during the production stage, leaving only the pure 150kDa active neurotoxin molecule in the final preparation.
Each vial of Botulax (taking 100 units as an example) contains 0.5mg of human serum albumin (HSA) and 0.9mg of sodium chloride (NaCl). Its pH value is usually maintained within the physiological range after reconstitution.
Xeomin differs in its choice of excipients. Each 100-unit vial contains 1.0mg of human serum albumin and 4.7mg of sucrose.
The addition of sucrose provides Xeomin with extremely high thermal stability, allowing it to be stored for up to 36 months at a room temperature of 25 degrees Celsius in an unopened state, whereas Botulax must be strictly transported and stored in a cold chain environment of 2 to 8 degrees Celsius.
From the perspective of quantitative protein load data, the difference in structure leads to a fundamental distinction in immunogenicity between the two:
- Xeomin: Contains only approximately 0.44ng of protein per 100 units of preparation, and all of this protein is the biologically active 150kDa neurotoxin.
- Botulax: The total protein amount per 100 units is approximately 4.5ng to 5ng, of which approximately 85% to 90% are inactive complex proteins without wrinkle-removing functions.
When the 900kDa Botulax is injected into muscle tissue, because the local pH value is approximately 7.4 (physiologically neutral), the complex proteins wrapped around the toxin will quickly fall off within minutes, releasing the 150kDa active portion.
During this process, the 750kDa of inactive proteins do not provide any therapeutic effect on the nerve junctions; they remain at the injection site or enter the lymphatic system and are recognized by the antigen-presenting cells of the immune system.
Once the immune system recognizes these foreign proteins as invaders, it activates B cells to produce neutralizing antibodies.
Because the 150kDa structure of Xeomin removes these “protective shells,” it significantly reduces the immune system’s chances of discovering foreign proteins.
From the details of the mechanism of action, the 150kDa active part is the only unit that performs the function.
Its 100kDa heavy chain is responsible for finding and binding with high affinity to the SV2 receptors on the surface of nerve endings, subsequently entering the neurons through endocytosis.
The 50kDa light chain is a zinc-dependent endopeptidase that precisely cleaves the SNAP-25 protein inside the cytoplasm.
SNAP-25 is a key mediator for the release of acetylcholine vesicles. Once destroyed, acetylcholine cannot be transmitted from the nerve to the muscle, thereby achieving muscle relaxation.
- Botulax Structure: Neurotoxin (150kDa) + Hemagglutinin (HA) + Non-hemagglutinin (NTNH) = 900kDa complex.
- Xeomin Structure: Highly purified 150kDa pure neurotoxin, without HA and NTNH.
- Molecular Diffusion Difference: Although the molecular weight of Xeomin is smaller, clinical studies show that under the same dilution ratio, the diffusion radius of the 150kDa molecule in tissue has no statistically significant difference from that of the 900kDa molecule. This indicates that diffusion is mainly affected by injection volume and pressure, rather than molecular weight.
Regarding manufacturing standards, Botulax uses highly automated biological fermentation and vacuum-drying technology to ensure the consistency of Specific Activity between batches. The coefficient of variation for its active units is strictly controlled at an extremely low level.
The manufacturing focus of Xeomin lies in eliminating impurities. It removes all non-toxin proteins through multi-stage chromatography. This depth of purification directly leads to its excellent performance in neutralizing antibody production rates.
According to years of clinical follow-up data, the proportion of patients using Xeomin long-term who produce neutralizing antibodies is close to zero, while among patients using preparations containing complex proteins (such as products similar to Botulax) long-term, approximately 1% to 3% will experience an increase in antibody levels, leading to a gradual weakening of drug efficacy.
Protein Content Quantification
For a standard dose of 100 units, there is an order of magnitude difference in the absolute mass of protein between different brands.
As one of the world’s most highly purified preparations, Xeomin contains a total protein mass of only 0.44ng per 100 units.
In contrast, Botulax follows the classic 900kDa complex production standard, with a protein mass of approximately 5ng per 100-unit preparation.
This difference in mass stems from the different molecular structures.
Of the 5ng of protein in Botulax, only about 1ng to 1.1ng is the truly effective 150kDa active neurotoxin; the remaining nearly 4ng are complex proteins (NAPs) without therapeutic function, such as hemagglutinin proteins and non-toxic non-hemagglutinin proteins.
Biologically, this increase in inactive protein load raises the risk of exposure for the human immune system to recognize foreign proteins and produce antibodies.
The table below shows a detailed comparison of the protein quantification parameters between Xeomin and Botulax, based on laboratory standard analysis results:
| Quantitative Indicator | Xeomin (Per 100 Units) | Botulax (Per 100 Units) | Difference Ratio |
|---|---|---|---|
| Total Protein Load | 0.44ng | Approx. 5.0ng | Approx. 11.3x |
| Active Neurotoxin Weight (150kDa) | 0.44ng | Approx. 1.1ng | Approx. 2.5x |
| Inactive Complex Protein Weight (NAPs) | 0ng | Approx. 3.9ng | Not Comparable |
| Specific Activity | 227 Units/ng | 20 Units/ng | Approx. 11.3x |
| Total Molecular Composition | 100% Active Molecules | Approx. 22% Active + 78% Impurity Protein | – |
Analyzing from the perspective of Specific Activity, Xeomin’s value is 227 Units/ng, demonstrating extremely high bioavailability. Every nanogram of protein contributes significant biological activity.
Because Botulax contains a large amount of inactive complex proteins, its specific activity is diluted to approximately 20 Units/ng.
In clinical application, if a user needs an injection of 300 units of botulinum toxin for the relaxation of large body muscle groups, the total foreign protein intake when using Xeomin is only 1.32ng, whereas when using Botulax, the total protein intake soars to around 15ng.
Immunological research points out that the probability of the human body producing neutralizing antibodies is positively correlated with the total protein amount of a single injection and the cumulative protein load over the long term.
When foreign proteins enter human tissue, antigen-presenting cells (APC) capture these protein fragments and present them to T cells and B cells.
Since the protein load of Botulax is more than 11 times that of Xeomin, its “visibility” to the immune system increases accordingly.
The quantification of protein content is not just a physical number; it is directly related to the effectiveness of long-term treatment.
In clinical statistics regarding botulinum toxin resistance, long-term follow-up data for 900kDa complex botulinum toxins (such as Botulax) shows that a certain percentage of patients have detectable neutralizing antibodies in their serum after multiple injections.
These antibodies usually first target the complex proteins and may subsequently expand to target the 150kDa active portion, leading to reduced or complete loss of therapeutic effect.
Because Xeomin removes all protein components except the 150kDa portion, its neutralizing antibody production rate was reported as 0% in multiple global multi-center clinical trials for first-time users.
This extremely low protein load makes Xeomin show superior biosafety in cases requiring high-frequency, large-dose injections.
Regarding production process details, Xeomin’s high purity relies on a sophisticated multi-stage chromatographic purification method, which can precisely cut the non-covalent bonds between the complex proteins and the neurotoxin at the molecular level.
This process ensures that the final product contains no redundant genetic material residues or cell culture proteins. Botulax uses vacuum-drying technology to maintain the structural integrity of its 900kDa complex.
Although Botulax also uses human serum albumin (HSA) as a stabilizer in its excipients, the 3.9ng of inactive endogenous protein it carries is the primary source leading to immune system reactions.
These endogenous complex proteins dissociate from the 150kDa active toxin after entering subcutaneous tissue with a neutral pH, becoming impurities in a free state.
Proteins
Xeomin only retains the 150kDa active toxin and does not contain complex proteins; the protein load per 100U preparation is only about 0.44ng.
Botulax is a 900kDa complex containing non-functional proteins such as hemagglutinin, and its total protein amount is more than 10 times that of Xeomin.
This structural difference directly affects immune response: Xeomin’s chance of producing neutralizing antibodies is close to 0%, while Botulax carries the risk of deteriorating efficacy due to protein-induced immune reactions during long-term or large-dose use.
Molecular Structure Differences
When discussing the molecular structure differences of Type A botulinum toxin, the values 150kDa and 900kDa represent fundamental divergences in pharmaceutical processes.
During the production process, Xeomin (IncobotulinumtoxinA) completely removes all non-functional proteins through multi-stage chromatographic purification. Its finished product contains only the core 150kDa neurotoxin.
This core consists of a heavy chain of approximately 100kDa and a light chain of approximately 50kDa, connected by a disulfide bond.
In contrast, Botulax (LetibotulinumtoxinA) adopts the traditional large-molecule botulinum toxin complex form, with a molecular weight of approximately 900kDa.
In this massive spherical structure, the 150kDa active toxin is wrapped among a group of complex auxiliary proteins.
These auxiliary proteins include hemagglutinin (HA) and non-toxin non-hemagglutinin (NTNH).
Since auxiliary proteins account for the vast majority of the molecular mass, under the same 100-unit dose, the total protein mass contained in Botulax is much higher than that in Xeomin.
| Structural Property | Xeomin (IncobotulinumtoxinA) | Botulax (LetibotulinumtoxinA) |
|---|---|---|
| Core Neurotoxin Molecular Weight | 150kDa | 150kDa |
| Overall Molecular Mass | 150kDa (Pure State) | 900kDa (Complex State) |
| Auxiliary Proteins (HA/NTNH) | None | Approx. 750kDa |
| Disulfide Bond Structure | Included (Connects Heavy/Light Chains) | Included (Connects Heavy/Light Chains) |
| Preparation Protein Load (per 100U) | Approx. 0.44 nanograms | Approx. 4.5 to 5.0 nanograms |
| Molecular Diameter | Approx. 10 nm | Approx. 25 to 40 nm |
The 900kDa complex inside Botulax is a natural product formed during the bacterial fermentation process.
These auxiliary proteins act as barriers in nature, preventing the toxin from being destroyed by acidic conditions or proteases in the environment.
However, in medical injection, once the drug solution enters human tissue, because the acidity/alkalinity (pH value) changes from the acidic environment in the vial (pH 4.0-6.0) to the physiological neutral environment of human tissue (pH 7.4), this 900kDa complex will quickly dissociate.
Experimental data shows that this dissociation process can be completed within 15 to 30 seconds after entering the muscle. The auxiliary proteins originally tightly wrapped around the toxin will fall off, releasing the 150kDa active ingredient inside.
Regardless of whether the initial molecular weight is 900kDa or 150kDa, the entity that truly enters the nerve endings to function is identical.
Xeomin’s advantage is that its state leaving the factory is already the pure form after dissociation, saving the dissociation process within the tissue.
| Protein Component | Function | Xeomin Content | Botulax Content |
|---|---|---|---|
| 150kDa Active Toxin | Blocks acetylcholine release, inhibits muscle contraction | 100% | Approx. 16% to 20% |
| Hemagglutinin (HA) | Protects toxin in natural state, non-functional in human body | 0% | Approx. 60% to 70% |
| Non-hemagglutinin (NTNH) | Maintains toxin structural stability | 0% | Approx. 15% to 20% |
| Excipients | Human Serum Albumin, Sucrose/Sodium Chloride | Included | Included |
Because it does not carry that part of heavy “baggage” protein, Xeomin’s active molecules exhibit extremely high uniformity in solution.
Each 100 units of Xeomin only contains approximately 0.44ng of protein, while Botulax, which contains auxiliary proteins, carries more than 10 times the non-essential protein weight under equivalent potency.
Although these auxiliary proteins do not participate in any nerve paralysis process, they remain at the injection site as exogenous proteins, increasing the probability of the immune system recognizing and marking them.
The 150kDa Xeomin molecular structure is extremely compact. Its heavy chain is responsible for finding and binding to receptors on the surface of nerve cells, and its light chain acts as a protease to cut the proteins responsible for vesicle fusion (SNAP-25).
Botulax’s 900kDa structure imitates the earliest botulinum toxin standards in its production process. The binding between its 150kDa toxin and auxiliary proteins mainly relies on non-covalent bonds.
This large molecule structure’s physical radius is significantly larger than Xeomin’s. In the vial’s dry powder state, the large molecule complex may exhibit better thermal stability.
However, in terms of clinical diffusivity, the performance of the two is very close.
Although the 900kDa volume is theoretically larger, due to the aforementioned rapid dissociation effect, Botulax almost immediately turns back into the 150kDa form to diffuse in the tissue fluid.
From a biochemical perspective, Xeomin’s 150kDa structure removes protein components with pro-inflammatory potential such as HA. HA proteins are considered in some studies to possibly cause slight local irritation to surrounding tissues.
Xeomin’s 150kDa pure structure shows extremely high symmetry under a microscope. Its amino acid sequence integrity is precisely preserved after chromatographic purification, removing fragmented proteins or inactivated toxin molecules produced during fermentation.
| Physical and Chemical Properties | Xeomin (150kDa) | Botulax (900kDa) |
|---|---|---|
| Production Process | Continuous Chromatographic Purification | Gradient Dilution and Precipitation |
| Stability Dependence | Intramolecular Chemical Bonds | Intermolecular Protein Wrapping |
| Biological Specific Activity | Extremely High (Strong activity per unit mass) | Medium (Diluted by impurity proteins) |
| Tissue Dissociation Need | No Dissociation Needed | Dissociation needed at pH 7.4 |
| Excipient Formula | 500 micrograms Human Serum Albumin | 500 micrograms Human Serum Albumin |
Since there are no complex protein chains tangled with each other, the 150kDa pure toxin is not prone to structural collapse at room temperature.
In Botulax’s 900kDa structure, the non-covalent binding between auxiliary proteins and the toxin has higher sensitivity to temperature fluctuations.
If the environmental temperature rises, this layer of shell proteins may undergo irreversible conformational changes, which in turn affects the stability of the internal active toxin.
At the amino acid level, Xeomin’s active 150kDa part has high homology with Botulax’s 150kDa part, but Xeomin precisely strips away non-functional proteins with negative charges, which changes the initial interaction between the molecule and the cell membrane in terms of charge distribution.
This difference in purification degree is not only a change in physical weight but also an increase in biochemical activity density, ensuring that in every injection into the human body, the proportion of active substances reaches the theoretical upper limit, greatly suppressing the total exposure of the human immune system to foreign proteins.
Impurity Protein Components
As a 900kDa large molecule complex, Botulax’s internal core neurotoxin only accounts for less than twenty percent of its total mass, which is the 150kDa part.
The remaining 750kDa of mass is entirely occupied by non-functional complex proteins, which are biologically called impurity proteins.
Specifically, these impurities are mainly composed of hemagglutinin proteins (HA) and non-toxin non-hemagglutinin proteins (NTNH).
In natural environments, botulinum bacteria secrete these proteins to protect the toxin from being decomposed by proteases in the highly acidic stomachs of animals.
However, in modern medical aesthetic intramuscular injections, this protective mechanism completely loses its necessity.
Xeomin uses highly sophisticated chromatographic purification technology to strip away this 750kDa protein “shell” at the production stage, thereby obtaining high-purity 150kDa active ingredients.
Comparative data shows that each 100 units of Xeomin only contains approximately 0.44 nanograms of total protein mass, whereas brands containing complex proteins like Botulax usually carry a total protein mass between 4.5 nanograms and 5 nanograms per 100 units.
- Hemagglutinin HA-33 Subunit: Molecular weight approx. 33kDa, the most numerous impurity protein in the complex, mainly responsible for binding to sugar structures on the cell surface.
- Hemagglutinin HA-17 Subunit: Molecular weight approx. 17kDa, assists HA-33 in forming a stable ring structure, enhancing the complex’s physical defense capability.
- Hemagglutinin HA-70 Subunit: Molecular weight approx. 70kDa, acts as a large molecule scaffold to firmly lock the active toxin inside the complex.
- Non-toxin Non-hemagglutinin NTNH: Molecular weight approx. 130kDa to 150kDa, its structure is highly similar to the active toxin but has no neurotoxicity, mainly playing a role in maintaining overall conformational stability.
- Residual Bacterial Proteins: Trace non-specific protein fragments left during the fermentation and initial extraction process, which are impurities not completely cleared in the process.
When Botulax is injected into muscle tissue, because the tissue fluid pH is approximately 7.4, while the environment inside the vial is usually maintained between pH 4.0 and 6.0, this environmental change causes the 900kDa structure to dissociate in a short time.
The HA and NTNH proteins originally wrapped around the toxin separate from the 150kDa active portion.
The separated impurity proteins do not disappear but remain as foreign bodies around the injection site.
Due to the massive molecular weight and complex structure of these proteins, they are easily captured by antigen-presenting cells in the lymphatic system.
This capture process is the starting point of an immune response. In contrast, the ingredient list of Xeomin completely removes HA and NTNH.
Statistical research shows that the load of impurity proteins is positively correlated with the production frequency of neutralizing antibodies.
Long-term use of products with a high load of impurity proteins like Botulax accumulates the risk of the body producing defensive antibodies with increased injection frequency and dosage.
At the biochemical level, hemagglutinin proteins are not only physical carriers but also have certain biological activities.
For example, the HA part can assist toxin penetration by destroying the junction structures of epithelial cells.
In Botulax’s 900kDa complex, HA proteins account for approximately 70% of the total mass.
These proteins not only increase the volume of the drug but also mask the biological activity sites of the internal 150kDa toxin to some extent.
In laboratory activity assays, Xeomin, after removing impurity proteins, exhibits extremely high specific activity because almost every nanogram of its substance is pure effective ingredient.
Botulax requires higher mass protein input to achieve the same clinical unit potency, which invisibly increases the total protein amount a patient receives in a single session.
For scenarios requiring large-dose injections, such as treating masseter hypertrophy, developed calf muscles, or trapezius hypertrophy, the difference in protein load for a single injection becomes even more pronounced.
Xeomin’s immune safety under large-dose applications is much higher than that of traditional 900kDa preparations containing a large amount of impurity proteins.
- Total Protein Comparison: Xeomin approx. 0.44ng/100U, traditional brands like Botulax approx. 4.5ng to 5ng/100U.
- Impurity Proportion: Non-functional proteins in Botulax account for over 80%, while in Xeomin they are close to 0%.
- Immune Risk Assessment: Higher impurity protein load increases the likelihood of activating B cells to produce neutralizing antibodies.
- Tissue Compatibility: Pure 150kDa toxin has simpler interactions in tissue, not involving complex protein dissociation kinetics.
- Preparation Stability: After removing impurity proteins, Xeomin’s chemical structure is more stable at room temperature and less prone to protein aggregation.
Traditional Botulax production mostly uses gradient dilution and simple precipitation processes, which make it difficult to completely eliminate NTNH and HA proteins tightly bound to the toxin.
Xeomin adopts a multi-stage purification process including ion exchange chromatography and size exclusion chromatography, which can precisely separate proteins of different molecular weights like a sieve, retaining only the core 150kDa chain.
Because impurity proteins are completely excluded, Xeomin’s finished product contains no extra amino acid sequences, greatly reducing the risk of so-called “off-target” immune reactions.
In ten-year follow-up studies, almost no cases of complete loss of efficacy due to neutralizing antibody production were found among the patient population using Xeomin.
For groups using products containing 750kDa impurity proteins, as the years of injection increase, some users experience shortened maintenance time, weakened drug efficacy, or even complete ineffectiveness.
The root of this difference lies in the immune system’s memory response to impurity proteins.
Once the body recognizes and remembers the structure of these proteins, every subsequent injection will quickly activate immune defenses, causing the active toxin to be neutralized by antibodies before it can function.
Immune Response Principles
During the injection of botulinum toxin, 150kDa active neurotoxin and the 750kDa complex proteins wrapping it have completely different biological properties in the eyes of the immune system.
After the 900kDa complex carried by Botulax enters the muscle, its massive molecular weight and complex protein conformation significantly increase the probability of being captured by dendritic cells (DCs).
These dendritic cells reside in tissues, specifically looking for foreign antigens and transmitting this information to the immune system.
Research shows that the hemagglutinin (HA) component in complex proteins not only provides physical wrapping but also acts more like a “natural adjuvant” biologically, enhancing the immune cells’ recognition of the 150kDa active toxin.
In contrast, since Xeomin removes all non-functional complex proteins and only contains 150kDa of pure toxin, it significantly reduces this possibility of being “marked” at the molecular level.
Immune cells patrol the injection area.
Complex proteins are recognized as invaders.
Dendritic cells capture large-molecule substances.
Immune alarms are quickly activated.
In the acidic environment of lysosomes, these proteins are cut into tiny peptide fragments.
Subsequently, these fragments are loaded onto MHC II molecules and transported to the cell surface to be presented to helper T cells (Th cells).
Because each 100 units of Botulax contains approximately 4.5 nanograms of total protein, the number of antigen epitopes it provides is much larger than Xeomin’s 0.44 nanograms.
Once helper T cells recognize these antigens, they secrete cytokines, commanding B cells to differentiate into plasma cells and begin large-scale production of antibodies specific to botulinum toxin.
According to clinical immunology data, these antibodies are mainly divided into two types: one type is binding antibodies that do not affect drug efficacy, and the other type is neutralizing antibodies (NAbs) that can block the active site.
Neutralizing antibodies usually precisely attack the receptor-binding domain at the end of the 150kDa neurotoxin heavy chain, causing the toxin to be unable to enter nerve endings.
For long-term users of products containing complex proteins, every injection triggers a secondary immune response, and the antibody titer rises with increased injection frequency and total dosage.
In clinical medicine, this situation is called secondary non-responsiveness.
Data records show that among groups using 900kDa complex products, approximately one to three percent of patients experienced a significant shortening of drug maintenance time after multiple injections, for example, reducing from an initial 4 to 6 months to less than 2 months.
When the antibody titer reaches a certain threshold, even if the injection dose is increased, the resulting paralysis effect will be minimal.
Xeomin’s R&D logic is based on cutting this immune chain. By eliminating unnecessary complex proteins in the production stage, it prevents the immune system from forming effective antigen memory.
Multiple independent studies worldwide have confirmed that among thousands of subjects receiving pure 150kDa toxin treatment, almost no new neutralizing antibody generation was detected.
Quantifying from the perspective of protein load, the total amount of inactive protein released by Botulax under the same biological potency is more than 10 times that of Xeomin.
This huge difference in protein load is particularly pronounced during large muscle group injections (such as trapezius or gastrocnemius), because a single large-dose injection exposes the human body to several times the protein antigens of a facial injection.
The presence of hemagglutinin (HA) induces a local slight inflammatory response. This inflammatory environment further attracts more immune cells to gather at the injection site, forming a “mini-factory” conducive to antibody production.
Because its molecular structure strips away these immune-inciting impurities, Xeomin can maintain a low profile in tissue, thereby avoiding the immune system’s radar monitoring.
Even during high-dose injections of over 200 units, the immune risk of pure 150kDa toxin remains at an extremely low level.
This explains why many patients who have already developed partial resistance to traditional 900kDa preparations can still obtain stable therapeutic feedback after switching to high-purity Xeomin.
The stability of protein conformation also indirectly affects the immune response. Botulax’s 900kDa complex is prone to partial denaturation under unstable transportation or storage conditions.
Denatured proteins often expose more hydrophobic groups that are usually hidden, forming tiny protein aggregates. The immune system’s response to these aggregates is much stronger than to monomeric proteins.
Because the complex protein chain entanglement is removed, Xeomin’s 150kDa molecular monomer exhibits stronger physical and chemical stability after reconstitution.
In pharmacological experiments, researchers observed that the simpler the monomeric protein structure, the weaker its ability to induce polyclonal immune responses.
By reducing the human body’s contact with non-functional amino acid sequences, Xeomin is actually protecting the long-term uptake capacity of acetylcholine receptors at the neuromuscular junction for the toxin.
For those users pursuing long-term, sustainable aesthetic maintenance, choosing purity at the molecular level is to avoid facing a situation of no medicine being available in the future, ensuring that the muscle’s response to the agent always remains highly efficient.
Resistance
As a 900kDa complex protein preparation, Botulax contains non-toxin components that increase the frequency of immune system recognition.
In contrast, Xeomin only contains 150kDa active neurotoxin, and the total protein amount per 100 units of product is only 0.44 nanograms.
Research shows that using high-purity preparations can control the risk of secondary treatment failure to below 0.2%, while products containing impurity proteins have a significantly higher antibody detection rate under long-term, high-frequency use.
Molecular Weight Determines Immune Response
The molecular weight of traditional botulinum toxin preparations like Botulax is usually labeled as 900kDa.
This massive molecular weight consists of the 150kDa active neurotoxin and approximately 750kDa of non-toxin complex proteins (NAPs).
These complex proteins include hemagglutinin proteins (HA-17, HA-34, HA-70) and non-toxin non-hemagglutinin proteins (NTNH).
In contrast, Xeomin introduces high-precision chromatographic purification technology into its production process, removing all non-essential complex proteins. The final product only retains the 150kDa pure neurotoxin.
This streamlining of molecular weight significantly reduces the total protein load per unit dose.
Experimental data shows that each 100 units of Xeomin only contains approximately 0.44 nanograms (ng) of protein, whereas the protein content of early 900kDa preparations could be as high as 5 nanograms or more.
When the 900kDa complex enters the human body, although these complex proteins dissociate from the active toxin within minutes in a physiological pH environment (approx. 7.4), these large-molecule proteins have a strong immune adjuvant effect before dissociation.
Hemagglutinin proteins can stimulate the activity of antigen-presenting cells such as dendritic cells, enhancing the immune system’s marking efficiency for toxin molecules.
Once the immune system recognizes and remembers these protein characteristics, plasma cells will secrete neutralizing antibodies against the toxin.
The 150kDa Xeomin structure is extremely simple and lacks these auxiliary proteins that can “wake up” the immune system.
The table below shows a detailed comparison of molecular composition parameters for preparations of different purities:
| Molecular Composition Characteristic Indicator | Botulax (900kDa Preparation) | Xeomin (150kDa Preparation) |
|---|---|---|
| Active Neurotoxin Molecular Weight | 150kDa | 150kDa |
| Auxiliary Protein Types (NAPs) | HA-17, HA-34, HA-70, NTNH | None (Completely Removed) |
| Total Protein Weight Per Dose (100U) | Approx. 0.73ng to 5ng | Constant approx. 0.44ng |
| Purification Technology Route | Traditional Vacuum-Drying/Salting Out | Patented Multi-stage Chromatography |
| Excipient Components | Human Serum Albumin + Sodium Chloride | Human Serum Albumin + Sucrose |
| Physiological Environment Dissociation Need | Required (Increases Immune Exposure) | Not Required (Exists in Active State) |
Clinical observations find that the production of resistance usually manifests as secondary non-responsiveness.
For long-term users of Botulax, because every injection carries a large amount of non-functional proteins, the cumulative risk of the body producing neutralizing antibodies rises with the number of injections.
According to a long-term follow-up study on the immunogenicity of botulinum toxin, after 3 to 5 years of continuous treatment with products containing complex proteins, some patients had significantly increased neutralizing antibody titers detected in their bodies.
These antibodies act like shields, intercepting and neutralizing the neurotoxin before it reaches the motor endplates.
Xeomin’s “naked toxin” design has shown extremely low immunogenicity in multiple clinical trials. In multi-center studies of thousands of subjects, no cases of treatment failure due to antibody production were found.
Molecular weight also determines the diffusion characteristics and stability of the drug between tissues.
Although 900kDa preparations exist as complexes in the vial, the complex proteins rapidly fall off at the moment of injection into muscle tissue due to changes in environmental pH.
This shedding process is actually uncontrolled and may form micro-inflammatory responses locally, thereby recruiting more immune cells to gather.
The table below lists the details of the impact of molecular weight structure differences on clinical performance:
| Clinical Impact Dimension | 900kDa Complex Structure | 150kDa Pure Structure |
|---|---|---|
| Immune Cell Recruitment Rate | High (Stimulated by Complex Proteins) | Extremely Low (Lacks Immune Inducers) |
| Antibody Neutralization Risk | Linear Growth Trend with Frequency | Maintains Baseline Level (Close to 0%) |
| Diffusion Diameter Control | Affected by Excipients/Dissociation Speed | Determined by Neurotoxin Itself, Predictable |
| Long-term Treatment Stability | 10th Injection may be Weaker than 1st | Maintains High Consistency over Long Term |
| Storage Stability | Usually Requires 2-8°C Refrigeration | High Purity; Some Versions are Room Temp |
In actual operation, the 900kDa structure provided by Botulax usually provides good muscle relaxation effects in the initial injection.
However, when dealing with large-dose needs, the total protein mass pushed in a single session increases sharply, exceeding the immune tolerance threshold, and the probability of inducing antibodies jumps significantly.
For users needing more than 200 units in a single injection, the advantage of the 150kDa molecular structure becomes very significant.
If the body has already developed a slight reaction to 900kDa products, such as finding that the maintenance time has shortened from 6 months to 3 months, switching to Xeomin, which contains no complex proteins, can effectively stop further stimulation of the immune system and avoid complete resistance.
From a biochemical perspective, the vacuum-drying process used by Botulax, while maintaining toxin activity, cannot precisely strip away impurities attached to the toxin like chromatography can.
Although these impurities are insignificant under a microscope, they are the triggers for immune recognition at the molecular level.
In Xeomin’s manufacturing process, every step of chromatographic separation eliminates impurity proteins of specific molecular weights, ensuring that only that segment of neurotoxin with the ability to cut SNAP-25 protein is bottled.
There are also subtle differences in the biomechanical performance after injection for products of different molecular weights.
The 900kDa large molecules are more prone to wall-hanging in dilution or loss inside the needle, whereas the 150kDa pure toxin is more evenly distributed in solution, with a higher density of active units per unit volume.
This high-density active distribution allows doctors to obtain more precise feedback when performing multi-point micro-injections, without worrying about diffusion deviations caused by non-functional protein occupation.
This difference based on molecular weight purification determines that Botulax is more suitable as an entry-level economical choice, while Xeomin is the preferred option for users pursuing long-term anti-aging who do not want to see diminishing therapeutic effects.
Clinical Manifestations of Resistance
Clinical resistance to botulinum toxin does not happen instantaneously; it usually presents as a progressive process from weakened drug efficacy to complete disappearance.
Primary non-responsiveness can be detected during the first injection. After receiving a standard dose of Botulax or other preparations, the contraction strength of the target muscle does not weaken at all during the 14-day peak period of drug efficacy.
This situation’s incidence in the population is extremely low, usually showing below 0.1% in statistics. In contrast, secondary non-responsiveness belongs to the acquired immune response and mostly occurs in groups receiving long-term injections of 900kDa complex protein preparations.
Clinical manifestations usually first show as a significant shortening of the drug maintenance cycle. Wrinkle-removing effects that could originally be maintained for 4 to 5 months reduce to 8 to 10 weeks after several consecutive injections.
As the neutralizing antibody titer in the body rises, the degree of muscle relaxation also significantly attenuates. Even if the injection dose is increased from 20 units to 50 units, the patient can still feel obvious muscle activity.
The table below lists the quantitative observation indicators for different stages of resistance characteristics:
| Resistance Grading | Clinically Observed Muscle Performance | Typical Maintenance Time Range | Feedback After Dose Increase |
|---|---|---|---|
| Initial Response (Normal) | Complete relaxation; no wrinkles at rest | 120 – 180 Days | Sensitive response; linear growth |
| Mild Resistance | Muscle movement limited but not paralyzed | 60 – 90 Days | Dose increase briefly maintains effect |
| Moderate Resistance | Only 30% to 50% of muscle power blocked | 30 – 45 Days | Dose doubling has little improvement |
| Severe/Complete Resistance | Muscle contraction as usual 14 days post-injection | 0 – 14 Days (Ineffective) | No biological reaction to any dose |
Before the immune system produces a large amount of neutralizing antibodies, the neurotoxin can quickly bind with the SV2 receptors of nerve endings after entering tissue.
Once there is a low concentration of antibodies in the blood, some toxin molecules will be intercepted before reaching the target, causing the drug’s onset time to extend from the usual 2 to 3 days to over 7 to 10 days.
The subsequent manifestation is the loss of “peak efficacy.” Electromyography (EMG) tests can find that the decrease in compound muscle action potential (CMAP) amplitude around the injection site is far lower than expected.
In normal cases, the CMAP amplitude after Botulax injection should drop by more than 80%, while patients developing resistance may only drop by about 20%.
This loss of efficacy not only reduces the visual effect of aesthetic improvement but also makes masseter or calf muscle hypertrophy issues originally treated with botulinum toxin difficult to solve through pharmaceutical means.
The current industry gold standard is the Mouse Protection Assay (MPA). By mixing a patient’s serum with a known dose of toxin and then injecting it into laboratory animals, it can be observed whether the toxin is neutralized by antibodies in the serum.
Another commonly used technology is the Enzyme-Linked Immunosorbent Assay (ELISA), used to screen for total antibody levels in the serum.
Research shows that when the concentration of neutralizing antibodies in the serum exceeds 0.24 mU/mL, patients will basically show obvious clinical loss of efficacy.
For users of high-purity Xeomin, due to the lack of immune stimulation from 750kDa complex proteins, the antibody detection rate stays close to 0% year-round.
For users frequently injecting large doses of Botulax, if the injection interval is frequently shorter than 12 weeks, the risk of producing antibodies will show exponential growth.
The distribution of risk factors inducing the aforementioned clinical resistance manifestations is as follows:
- Total Protein Load per Single Injection: The higher the mass of non-functional protein pushed into muscle tissue in a single session, the greater the probability of inducing B cells to produce antibodies. Xeomin contains only 0.44ng protein per 100U, whereas unpurified preparations can have several times that load.
- Too Dense Injection Frequency: Performing multiple “micro-adjustment touch-ups” within 3 months keeps the immune system in a state of continuous stimulation. This is a common operational error leading to secondary non-responsiveness.
- Cumulative Total Injection Amount: During long-term treatment, after the total amount of toxin protein the body has been in contact with reaches a certain threshold, the immune system will form permanent immune memory.
- Preparation Purification Process Differences: Preparations using vacuum-drying processes produce more damaged toxin molecules during production. Although these damaged molecules have no therapeutic activity, they retain immunogenicity.
Patients need to stop all types of botulinum toxin injections for at least 12 to 18 months to observe whether the antibody titer in the body will decrease over time.
However, once the immune system has formed a strong memory response, even after a two-year drug holiday, the antibody titer may still quickly rebound when re-injecting Botulax containing complex proteins.
For this type of group, switching to Xeomin, which contains no complex proteins, is a solution generally recognized in the medical community.
Because Xeomin strips away all non-essential auxiliary proteins, its extremely low biological load is unlikely to trigger existing immune memory, thereby allowing botulinum toxin treatment that had previously “failed” to regain clinical response.
At the histological level, resistance also manifests as abnormalities in the nerve re-innervation process.
During normal drug efficacy periods, nerve endings produce temporary sprouts to compensate for the blocked function. As the toxin is degraded, original nerve function recovers.
In resistant patients, because the toxin cannot effectively cut the SNAP-25 protein, nerve transmission remains smooth. The maintenance of this physiological balance is manifested by the lack of any muscle volume atrophy after injection.
In treatments targeting large muscle groups (such as the trapezius), if a patient does not observe visual changes in the shoulder line within the first month, and muscle hardness does not decrease during palpation, it usually predicts that neutralizing antibodies have begun to interfere with the drug’s function.
This immune escape from large-dose preparations determines that choosing a purer 150kDa preparation for body contouring treatment has more predictable long-term benefits than choosing traditional 900kDa preparations.
Total Protein & Injection Habits
As a traditional 900kDa preparation, Botulax wraps a large amount of hemagglutinin and non-hemagglutinin proteins in addition to the 150kDa active ingredient.
The content of these non-active proteins in the preparation significantly affects the human body’s immune load.
Laboratory analysis shows that the total protein mass in each 100 units of carrier varies quantitatively between different brands of botulinum toxin.
Through a multi-stage chromatographic purification process, Xeomin compresses the protein load per 100 units of product to approximately 0.44 nanograms.
In contrast, preparations containing complex proteins usually fluctuate between 0.73 nanograms and 5 nanograms of protein load at the same dose.
Elevated protein load increases the frequency of the immune system recognizing foreign antigens. This phenomenon is particularly evident in long-term, high-dose clinical applications.
Protein load determines immune frequency.
150kDa preparations strip away auxiliary proteins.
Purity differences affect antibody production rate.
In the long-term management of botulinum toxin, the interaction between injection habits and total protein amount is the main cause of treatment failure.
The immune system’s memory for proteins has a cumulative effect. The larger the single injection dose, the more non-functional proteins are pushed into the body.
The table below compares the immune risk distribution under different injection habits:
| Injection Behavior Dimension | Low Risk Operational Standard | High Risk Operational Characteristic |
|---|---|---|
| Single Injection Dose | Less than 100 Units (e.g., single area wrinkle) | Over 200 Units (e.g., trapezius or calf) |
| Injection Interval Cycle | Strictly follow 12 weeks (3 months) or more | Shorter than 8 weeks or frequent touch-ups |
| Preparation Purity Choice | Choose 150kDa preparation without complex proteins | Long-term use of preparation with 750kDa auxiliary proteins |
| Cumulative Total Injection Amount | Total annual dose controlled below 400 Units | Total annual dose over 800 Units |
Although the auxiliary proteins in Botulax do not participate in muscle relaxation, they act as immune adjuvants.
After these proteins enter tissue, they attract dendritic cells to gather, thereby efficiently presenting toxin characteristics to the immune system.
If a user maintains a habit of injecting every 2 months, the immune system will consider this a continuous pathogen invasion, thereby producing neutralizing antibodies.
Clinical study records show that in groups with shortened injection intervals, the detection rate of neutralizing antibodies is several times higher than in groups following the 12-week interval.
For users needing large-dose injections, since the absolute value of protein entering the body in a single session is extremely high, choosing a product with ultra-low protein load like Xeomin can significantly reduce the stimulation level of the immune system.
Frequent touch-ups increase immune memory.
12 weeks is the safety window for immune response.
Dose accumulation breaks through the immune tolerance threshold.
Treatment for fine facial wrinkles usually only requires 20 to 50 units. At this time, the total protein difference between Botulax and Xeomin is within the range acceptable to the immune system.
However, during body contouring (such as shoulder or leg thinning), the single dose often reaches 200 units or even more.
The table below shows the cumulative amount of complex proteins in preparations under different doses:
| Clinical Application Scenario | Injection Dose (Units) | Xeomin Total Protein (ng) | Traditional 900kDa Total Protein (ng) |
|---|---|---|---|
| Forehead/Crow’s Feet | 20 U | Approx. 0.088 ng | 0.146 ng – 1.0 ng |
| Masseter Hypertrophy | 100 U | 0.44 ng | 0.73 ng – 5.0 ng |
| Trapezius Adjustment | 200 U | 0.88 ng | 1.46 ng – 10.0 ng |
| Gastrocnemius Adjustment | 300 U | 1.32 ng | 2.19 ng – 15.0 ng |
When the mass of protein pushed in a single session exceeds 10 nanograms, the response intensity of the immune system undergoes a qualitative change.
Long-term high-frequency use of high-protein-load preparations keeps the antibody titer in the blood at a high level, causing subsequent injected toxin to be neutralized before reaching nerve junctions.
Habitual “low-dose multiple” injections (i.e., performing small dose supplements within 2 weeks after the main injection) are the least recommended behavior clinically.
This behavior generates an immune cascade reaction because the second injection is exactly during the active period of the initial immune response, making it extremely easy to induce neutralizing antibodies against the active toxin.
To maintain long-term treatment effectiveness, it is recommended that when performing large-scale muscle adjustments, priority should be given to Xeomin with lower total protein, and injections for all parts should be combined in the same session to avoid repeated stimulation of the immune system in a short time.
Large-dose injections should prioritize pure toxin.
Avoid secondary micro-adjustments within 14 days.
Protein load increases positively with dosage.
Botulax usually uses human serum albumin as a stabilizer. Although this is an endogenous protein, in cases of imperfect purification processes, culture medium protein impurities used during production may remain in the preparation.
Xeomin’s patented purification process not only removes complex proteins but also minimizes inactive damaged toxin molecules.
Damaged toxin molecules lose their nerve-blocking function, but their molecular structure remains intact enough to be recognized by the immune system and produce antibodies.
By using multi-stage chromatographic purification, Xeomin ensures that almost every nanogram of protein entering the body is a 100% biologically active 150kDa molecule.
In actual skin management plans, establishing correct injection records is very important to avoid resistance.
This includes recording the specific dose, preparation brand, and precise interval date of each injection.
If a user has consistently used Botulax for the past 2 years and feels the maintenance time has shortened from 5 months to 2 months, this is usually a signal that the immune system is reacting to the 900kDa complex proteins.